News

Caretaker Medical Chosen as Finalist to Compete for $350,000 Grand Prize at MedTech Conference

This year brought in a record number of applications with over 1,100 submissions from 54 countries and 42 U.S. states. With less than a 5% acceptance rate, 50 companies were selected to participate in the MedTech Innovator Showcase, with a subset receiving a place in the MedTech Innovator Accelerator. Over four months, 25 Accelerator companies competed for a coveted spot in the Grand Finals. The five finalists are developing medical technology innovations in remote monitoring, patient safety and satisfaction, and prevention:

  • Alva Health (New Haven, CT) is developing a real-time, wearable stroke monitor for older Americans living with high stroke risk.
  • BioDevek (Brookline, MA) is developing an endoscopically-sprayable adhesive hydrogel to seal and protect surgical lesions after polyp removal.
  • Caretaker Medical (Charlottesville, VA ) is developing a wireless finger sensor for continuous “beat by beat” blood pressure and hemodynamics remote monitoring.
  • Cooler Heads Care (San Diego, CA) is developing an affordable wearable device so chemo patients can keep their hair.
  • Nutromics (Brunswick, AUS) is developing a wearable continuous molecular monitoring platform that can track drugs, hormones, metabolites, and proteins.

The final competition will be both live in-person as well as livestreamed on Wednesday, Sept. 29 at 12:00 PM ET during the The MedTech Conference. Viewers will vote online and in-person to decide who takes home the $350,000 Grand Prize and title of MedTech Innovator 2021. Register to watch the competition livestream here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation